INDEPENDENCE CONTRACT DRILLI (ICD) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:ICD • US4534156066

0.5858 USD
-0.06 (-9.88%)
At close: Aug 28, 2024
0.555 USD
-0.03 (-5.26%)
After Hours: 8/28/2024, 8:04:00 PM
Fundamental Rating

1

Taking everything into account, ICD scores 1 out of 10 in our fundamental rating. ICD was compared to 61 industry peers in the Energy Equipment & Services industry. Both the profitability and financial health of ICD have multiple concerns. ICD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ICD had negative earnings in the past year.
  • ICD had a positive operating cash flow in the past year.
  • ICD had negative earnings in each of the past 5 years.
  • Of the past 5 years ICD 4 years had a positive operating cash flow.
ICD Yearly Net Income VS EBIT VS OCF VS FCFICD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

  • ICD has a worse Return On Assets (-15.80%) than 92.06% of its industry peers.
  • ICD has a worse Return On Equity (-37.58%) than 87.30% of its industry peers.
Industry RankSector Rank
ROA -15.8%
ROE -37.58%
ROIC N/A
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ICD Yearly ROA, ROE, ROICICD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20 -30

1.3 Margins

  • In the last couple of years the Operating Margin of ICD has grown nicely.
  • The Gross Margin of ICD (32.59%) is better than 65.08% of its industry peers.
  • ICD's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ICD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.59%
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
ICD Yearly Profit, Operating, Gross MarginsICD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

  • ICD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ICD has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ICD is higher compared to a year ago.
ICD Yearly Shares OutstandingICD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
ICD Yearly Total Debt VS Total AssetsICD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

  • ICD has an Altman-Z score of -1.26. This is a bad value and indicates that ICD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.26, ICD is doing worse than 88.89% of the companies in the same industry.
  • ICD has a debt to FCF ratio of 10.37. This is a negative value and a sign of low solvency as ICD would need 10.37 years to pay back of all of its debts.
  • ICD has a Debt to FCF ratio of 10.37. This is comparable to the rest of the industry: ICD outperforms 46.03% of its industry peers.
  • A Debt/Equity ratio of 1.08 is on the high side and indicates that ICD has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.08, ICD is not doing good in the industry: 79.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 10.37
Altman-Z -1.26
ROIC/WACCN/A
WACC2.02%
ICD Yearly LT Debt VS Equity VS FCFICD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.33 indicates that ICD should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.33, ICD is doing worse than 79.37% of the companies in the same industry.
  • A Quick Ratio of 1.28 indicates that ICD should not have too much problems paying its short term obligations.
  • The Quick ratio of ICD (1.28) is worse than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 1.28
ICD Yearly Current Assets VS Current LiabilitesICD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

  • ICD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -662.07%.
  • ICD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.60%.
  • Measured over the past years, ICD shows a quite strong growth in Revenue. The Revenue has been growing by 8.06% on average per year.
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%

3.2 Future

  • ICD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -46.50% yearly.
  • ICD is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -8.70% yearly.
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICD Yearly Revenue VS EstimatesICD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ICD Yearly EPS VS EstimatesICD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2 -4 -6 -8 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ICD. In the last year negative earnings were reported.
  • Also next year ICD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICD Price Earnings VS Forward Price EarningsICD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ICD is valued a bit cheaper than the industry average as 74.60% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, ICD is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.54
EV/EBITDA 4.69
ICD Per share dataICD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as ICD's earnings are expected to decrease with -46.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.5%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • ICD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDEPENDENCE CONTRACT DRILLI

NYSE:ICD (8/28/2024, 8:04:00 PM)

After market: 0.555 -0.03 (-5.26%)

0.5858

-0.06 (-9.88%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)08-07
Earnings (Next)10-30
Inst Owners0.01%
Inst Owner Change0%
Ins Owners75.82%
Ins Owner Change0%
Market Cap8.92M
Revenue(TTM)179.95M
Net Income(TTM)-59.25M
Analysts80
Price Target3.57 (509.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.38%
Min EPS beat(2)-50.58%
Max EPS beat(2)-2.18%
EPS beat(4)0
Avg EPS beat(4)-48.02%
Min EPS beat(4)-115.7%
Max EPS beat(4)-2.18%
EPS beat(8)4
Avg EPS beat(8)27.37%
EPS beat(12)5
Avg EPS beat(12)-68.42%
EPS beat(16)9
Avg EPS beat(16)-49.21%
Revenue beat(2)2
Avg Revenue beat(2)6.69%
Min Revenue beat(2)2.48%
Max Revenue beat(2)10.9%
Revenue beat(4)3
Avg Revenue beat(4)3.1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)10.9%
Revenue beat(8)6
Avg Revenue beat(8)2.51%
Revenue beat(12)8
Avg Revenue beat(12)2.8%
Revenue beat(16)9
Avg Revenue beat(16)0.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-48.55%
EPS NQ rev (3m)-25.02%
EPS NY rev (1m)-36.74%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-14.34%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-3.15%
Revenue NY rev (3m)-5.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF 0.54
P/OCF 0.21
P/B 0.06
P/tB 0.06
EV/EBITDA 4.69
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)1.09
FCFY186.61%
OCF(TTM)2.86
OCFY487.46%
SpS11.83
BVpS10.37
TBVpS10.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.8%
ROE -37.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.59%
FCFM 9.24%
ROA(3y)-13.85%
ROA(5y)-15.34%
ROE(3y)-28.45%
ROE(5y)-28.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y66.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.54%
GM growth 5Y2.72%
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 10.37
Debt/EBITDA 4.57
Cap/Depr 58.68%
Cap/Sales 14.9%
Interest Coverage N/A
Cash Conversion 116%
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 1.28
Altman-Z -1.26
F-Score3
WACC2.02%
ROIC/WACCN/A
Cap/Depr(3y)80.67%
Cap/Depr(5y)71.77%
Cap/Sales(3y)20.36%
Cap/Sales(5y)19.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-662.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-942.86%
EPS Next Y-146.84%
EPS Next 2Y-46.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.6%
Revenue growth 3Y36.07%
Revenue growth 5Y8.06%
Sales Q2Q%-23.12%
Revenue Next Year-20.87%
Revenue Next 2Y-8.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-138.99%
EBIT growth 3YN/A
EBIT growth 5Y79.64%
EBIT Next Year42.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2030.36%
OCF growth 3Y494.79%
OCF growth 5Y30.47%

INDEPENDENCE CONTRACT DRILLI / ICD FAQ

What is the fundamental rating for ICD stock?

ChartMill assigns a fundamental rating of 1 / 10 to ICD.


What is the valuation status for ICD stock?

ChartMill assigns a valuation rating of 2 / 10 to INDEPENDENCE CONTRACT DRILLI (ICD). This can be considered as Overvalued.


Can you provide the profitability details for INDEPENDENCE CONTRACT DRILLI?

INDEPENDENCE CONTRACT DRILLI (ICD) has a profitability rating of 2 / 10.


How financially healthy is INDEPENDENCE CONTRACT DRILLI?

The financial health rating of INDEPENDENCE CONTRACT DRILLI (ICD) is 1 / 10.